In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Building the New Generation of Drugs in Neurodegeneration

Executive Summary

Neurodegenerative diseases have emerged as one of the toughest and potentially most attractive frontiers in specialty drug development. Companies interested in the NDD space have the option of pursuing several strategies: disease-modifying therapies, symptom management therapies, or a hybrid approach, in which symptom-modifying drugs provide near-term revenues but also have longer-term potential for disease modification. Given the extraordinary difficulty associated with producing a successful disease-modifying new therapy, drugs aimed at treating symptoms are likely to dominate the NDD space for years. Licensors are rewarding developers with promising symptom modification programs with attractive deals.
Advertisement

Related Content

Will New Drugs For Motor Symptoms Of Parkinson's Disease Deliver?
Will New Drugs For Motor Symptoms Of Parkinson's Disease Deliver?
Biomarkers For Alzheimer's, Parkinson's Disease To Be Developed By Industry Coalition Through First-Of-A-Kind Clinical Data Exchange
J&J And Elan Strike A Deal On Key Alzheimer's Disease Assets
Elan's High Wire Act Finds a Semi-Safe Net
Elan's High Wire Act Finds a Semi-Safe Net
The Alzheimer's Divide
The Alzheimer's Divide

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003438

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel